Author name: DrugPatentWatch

Unit price is the number everyone fights over. It’s also the number that matters least. Pharmaceutical procurement has a dirty […]

The Clock You Can Buy In the drug industry, time is not just money. It is the only thing that

Introduction: The Law That Reshaped American Medicine In 1984, a California congressman named Henry Waxman and a Utah senator named

The Problem With Waiting Most formulation vendors approach business development reactively. They wait for a drug to lose exclusivity, watch

There’s a quiet shift happening in pharmacology that doesn’t show up neatly in prescribing guidelines or FDA labels. It shows

The Number Nobody Puts in the Model Every pharma M&A deal starts with a revenue forecast. Bankers build complex discounted

Every pharmaceutical executive knows the word “patent cliff.” Fewer can accurately define the legal machinery underneath it. Fewer still understand

Why Your LOE Strategy Depends on Molecule Type A brand-name drug losing its final patent is not one event. It

Every year, billions of euros in pharmaceutical procurement value shifts from branded drug budgets to competitive tender processes across the